This story has been updated to clarify Luis Diaz's affiliation with liquid biopsy firm PGDx.

NEW YORK (GenomeWeb) – Liquid biopsy firm Cynvenio Biosystems announced earlier this month that it is now offering a blood-based monitoring service to track disease status or to surveil for early signs of recurrence in breast cancer patients.

This type of monitoring has been the focus of significant attention amongst liquid biopsy researchers. But to date, most clinical testing remains limited to less frequent analyses.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.